Organization | Anhui Medical University

Anhui Medical University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Hefei China (1926)

Organization Overview

First Clinical Trial

2005

NCT00520247

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

1st Affiliated Hospital, Anhui Medical University | 2nd Affiliated Hospital, Anhui Medical University | Anhui Cancer Hospital | Anhui Chest Hospital | Anhui Jimin Cancer Hospital | Anhui Medical University | Anhui Medical University Affiliated Children's Hospital, China | Anhui Medical University Affiliated First Hospital | Anhui Medical University Second Hospital | Anhui Mental Health Center | Anhui Province Cancer Center | Anhui Province Children's Hospital | Anhui Province Hospital | Anhui provincial cancer hospital | Anhui Provincial Cancer Hospital | Anhui Provincial Children's Hospital | Anhui Provincial Hospital | Anhui Provincial Hospital of Traditional Chinese Medicine | Anqing Research Center of Anhui Medical University Biomedical Institute | Biomedical Institute of Anhui Medical University | Dan Su | Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University | Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University | Department of Nephrology, 2nd Affiliated Hospital of Anhui Medical University, Anhui | E.N.T. department of the First Affiliated hospital of Anhui Medical University | First affiliated Hospital of Anhui Medical University | First Affiliated Hospital of Anhui Medical University | First affiliated Hospital of Anhui Medical University Locations: China, | First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | The First Affiliated Hospital of Anhui Medical University | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | The First Hospital of Anhui Medical University | The Fourth Affiliated Hospital of Anhui Medical University | the Second Affiliated Hospital of Anhui Medical University | The Second Hospital of Anhui Medical University | The Third Affiliated Hospital of Anhui Medical University

Active Ingredients

Drugs in Phase 4 Trials (41)

avatrombopag (2 trials)

carboplatin (paraplatin) (1 trial)

cinacalcet (sensipar) (1 trial)

cisplatin (platinol) (3 trials)

crizotinib (xalkori) (1 trial)

deng zhan sheng mai (1 trial)

dexamethasone (3 trials)

dexmedetomidine (precedex) (7 trials)

docozine (1 trial)

donafenib (1 trial)

enalapril (vasotec) (3 trials)

endostatin (endostar) (3 trials)

entecavir (baraclude) (1 trial)

epinephrine (levophed) (1 trial)

ethambutol (myambutol) (1 trial)

etoposide (vepesid) (2 trials)

fentanyl (Innovar) (1 trial)

folic acid (4 trials)

immune globulin (human) (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

isoniazid (nydrazid) (1 trial)

ixazomib (ninlaro) (1 trial)

lauromacrogol (1 trial)

levofloxacin (levaquin) (1 trial)

midazolam (versed) (1 trial)

octreotide (sandostatin) (1 trial)

oseltamivir (tamiflu) (2 trials)

pemetrexed (alimta) (1 trial)

pomalidomide (pomalyst) (1 trial)

prednisone (meticorten) (5 trials)

pyrazinamide (Aldinamide) (1 trial)

reduning (1 trial)

ribavirin (virazole) (1 trial)

rifampin (1 trial)

ruxolitinib (jakafi) (1 trial)

sodium chloride (4 trials)

somatropin (protropin) (2 trials)

terlipressin (2 trials)

urea (8 trials)

xingnaojing (1 trial)

zinc gluconate (1 trial)

Drugs in Phase 3 Trials (40)

acetylsalicylic acid (aspirin) (2 trials)

aclarubicin (1 trial)

amlodipine (norvasc) (2 trials)

caffeic acid (1 trial)

capecitabine (xeloda) (3 trials)

cetuximab (erbitux) (1 trial)

cladribine (leustatin) (1 trial)

cyclophosphamide (cytoxan) (4 trials)

cytarabine (cytosar-u) (3 trials)

decitabine (dacogen) (1 trial)

docetaxel (taxotere) (1 trial)

epirubicin (ellence) (1 trial)

filgrastim (neupogen) (1 trial)

fluorouracil (efudex) (3 trials)

gelatin (1 trial)

gimeracil (2 trials)

huachansu pian (1 trial)

icaritin (2 trials)

irbesartan (avapro) (1 trial)

irinotecan (Camptosar) (1 trial)

lipiodol (1 trial)

methylprednisolone (medrol) (1 trial)

mycophenolate (myfortic) (1 trial)

nadroparin (2 trials)

omacetaxine (synribo) (1 trial)

oteracil (2 trials)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (3 trials)

rc48-adc (1 trial)

rituximab (rituxan) (2 trials)

rivaroxaban (xarelto) (2 trials)

semustine (1 trial)

sintilimab (2 trials)

sorafenib (nexavar) (2 trials)

tegafur (2 trials)

thalidomide (Thalomid) (2 trials)

thrombopoietin (2 trials)

vinorelbine (navelbine) (1 trial)

warfarin (coumadin) (2 trials)

Drugs in Phase 2 Trials (24)

almonertinib (1 trial)

apatinib (5 trials)

azacitidine (vidaza) (1 trial)

bevacizumab (avastin) (2 trials)

chidamide (1 trial)

diacerein (1 trial)

doxorubicin (Doxil) (1 trial)

eltrombopag (promacta) (1 trial)

envafolimab (2 trials)

erlotinib (tarceva) (2 trials)

gefitinib (iressa) (1 trial)

glumetinib (1 trial)

icotinib (1 trial)

jueyin (1 trial)

lenalidomide (revlimid) (1 trial)

lenvatinib (lenvima) (2 trials)

niraparib (zejula) (1 trial)

pamiparib (2 trials)

pcar-019 (2 trials)

pembrolizumab (keytruda) (1 trial)

sitravatinib (1 trial)

surufatinib (1 trial)

tislelizumab (2 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (21)

aripiprazole (abilify) (1 trial)

autologous natural killer cells (1 trial)

cd19 allo-car-t cells (1 trial)

cd19 car-t cells (3 trials)

cd22 car-t cells (2 trials)

cd7 car gd T cells (1 trial)

cd7 car-t cell (1 trial)

fludarabine (fludara) (2 trials)

lcar-m23 (1 trial)

ly-covmab (1 trial)

melphalan (alkeran) (2 trials)

mifepristone (mifeprex) (1 trial)

olanzapine (zyprexa) (1 trial)

pentoxifylline (trental) (1 trial)

pertuzumab (perjeta) (1 trial)

probiotic (1 trial)

risperidone (risperdal) (1 trial)

shen26 (1 trial)

tangshen (1 trial)

thiscart19 (1 trial)

triptorelin (Trelstar) (1 trial)

Drugs in Other Trials (34)

azathioprine (imuran) (2 trials)

benazepril (lotensin) (1 trial)

chlorhexidine (hibitane) (1 trial)

dalteparin (fragmin) (1 trial)

esketamine (spravato) (2 trials)

flurbiprofen (ansaid) (1 trial)

forsythia suspensa (1 trial)

forsythia vahl (1 trial)

gardenia jasminoides ellis (1 trial)

glucosamine (1 trial)

gucy2c cart cells (1 trial)

huaier (1 trial)

hydroxychloroquine (plaquenil) (2 trials)

ibuprofen (motrin) (1 trial)

ismigen (1 trial)

ketoconazole (nizoral) (1 trial)

leflunomide (arava) (2 trials)

lidocaine (xylocaine) (1 trial)

methotrexate (1 trial)

methylcobalamin (1 trial)

nalbuphine (nubain) (1 trial)

nicotinamide (1 trial)

norepinephrine (levophed) (1 trial)

propofol (diprivan) (2 trials)

ropivacaine (naropin) (1 trial)

scutellaria baicalensis georgi (1 trial)

sevoflurane (ultane) (1 trial)

sufentanil (1 trial)

taa05 (1 trial)

terazosin (hytrin) (1 trial)

valsartan (diovan) (1 trial)

vitamin c (1 trial)

xinfeng (2 trials)

xiyanping (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Adenocarcinoma (Phase 4)

Adenocarcinoma of Lung (Phase 4)

Anxiety Disorders (Phase 1)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cerebral Infarction (Phase 4)

Colorectal Neoplasms (Phase 3)

Confusion (Phase 4)

Delirium (Phase 4)

Depressive Disorder (Phase 1)

Depressive Disorder, Major (Phase 1)

Diabetic Nephropathies (Phase 1)

Disease (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

Dwarfism, Pituitary (Phase 4)

Endocrine System Diseases (Phase 4)

Enterocolitis (Phase 1)

Esophageal Neoplasms (Phase 3)

Esophageal Squamous Cell Carcinoma (Phase 2)

Essential Hypertension (Phase 4)

Glomerulonephritis, IGA (Phase 3)

Hemorrhage (Phase 4)

Hemorrhoids (Phase 4)

Herpangina (Phase 4)

Hirschsprung Disease (Phase 1)

Hyperhomocysteinemia (Phase 3)

Hyperparathyroidism (Phase 4)

Hyperparathyroidism, Secondary (Phase 4)

Hypertension (Phase 4)

Influenza, Human (Phase 4)

Ischemia (Phase 4)

Kidney Diseases (Phase 3)

Leukemia (Phase 3)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Prolymphocytic (Phase 2)

Leukemia, Prolymphocytic, B-Cell (Phase 2)

Leukemia, T-Cell (Phase 3)

Liver Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 4)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 1)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Anaplastic (Phase 4)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 4)

May-Thurner Syndrome (Phase 3)

Neoplasm Metastasis (Phase 4)

Neoplasms (Phase 1)

Neoplasms, Plasma Cell (Phase 1)

Neoplasms, Squamous Cell (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatitis (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 3)

Psoriasis (Phase 2)

Purpura (Phase 4)

Purpura, Thrombocytopenic (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 4)

Recurrence (Phase 3)

Schizophrenia (Phase 1)

Stomach Neoplasms (Phase 3)

Stroke (Phase 4)

Thrombocytopenia (Phase 3)

Thromboembolism (Phase 3)

Thrombosis (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Pulmonary (Phase 4)

Uterine Cervical Neoplasms (Phase 2)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 127
# of Trial APIs: 160